Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28953272 | 0.98 | PPM1B (0.46) | PPM1BPTPN1PPP1CCGABRPGABRD | |
| SCHEMBL4917731 | 0.89 | GNAI3 (0.47) | PPM1BPTPN1PPP1CCGABRPGABRD | |
| SCHEMBL6063290 | 0.89 | PPM1B (0.41) | PPM1BPTPN1PPP1CCGABRPGABRD | |
| Bromide SCHEMBL11562531 | 0.87 | GNAI3 (0.46) | PPM1BPTPN1PPP1CCGABRPGABRD | |
| SCHEMBL13610197 | 0.86 | GNAI3 (0.53) | TSHRGNAI3GNAO1GNAI1 | |
| SCHEMBL6141464 | 0.86 | — | — | |
| SCHEMBL526510 | 0.86 | PPM1B (0.55) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| Ethyl Isonipecotate SCHEMBL27886 | 0.84 | MAPT (0.51) | PPM1BPTPN1PPP1CCGABRPGABRD | |
| Ethyl Isonipecotate SCHEMBL6439825 | 0.84 | MAPT (0.51) | PPM1BPTPN1PPP1CCGABRPGABRD | |
| SCHEMBL27661510 | 0.83 | TSHR (0.42) | GABRPGABRDGABRA1TSHRGABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | claimed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | claimed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | claimed |
| US-7427606-B2 | Method to reduce inflammatory response in transplanted tissue | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-23 | — | — | US | claimed |
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | claimed |
| US-7378400-B2 | Method to reduce an inflammatory response from arthritis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-27 | — | — | US | claimed |
| JP-2008508360-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1496911-B1 | USE OF A COMBINATION COMPRISING A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV VIRGINIA (US) | 2007-12-19 | — | — | EP | claimed |
| CN-101068825-A | Having a2A2-propynyl adenosine analogs with modified 5' -ribose groups for agonist activity | UNIV VIRGINIA (US) | 2007-11-07 | — | — | CN | claimed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | claimed |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | claimed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | claimed |
| WO-2005107463-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | claimed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | claimed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | PPM1B 1369/4885PTPN1 1528/4885PPP1CC 3576/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | PPM1B 599/4885PTPN1 3396/4885PPP1CC 2594/4885 |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | ADORA2A, PDE4A, PDE4B | PPM1B 613/4885PTPN1 2999/4885PPP1CC 2089/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | PPM1B 2118/4885PTPN1 2092/4885PPP1CC 4309/4885 |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | PPM1B 4036/4885PTPN1 4673/4885PPP1CC 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.